Condition
Refractory Metastatic Colorectal Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Refractory Metastatic Colorectal Cancer clinical trials that are recruiting, at sites in 10 countries (most in China (2), Germany (2), Czechia (1)). 1 was first registered in the last 30 days. By phase: Phase 2 (2), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1New in 30 days
- 10Countries
Newest Refractory Metastatic Colorectal Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies | Phase 2 | Wuhan, Hubei | Recruiting | Oct 26, 2026 |
| Suvemcitug plus trifluridine/tipiracil for refractory metastatic colorectal cancer | Phase 3 | Fuzhou, Fujian and 5 other locations | Recruiting | Jan 22, 2026 |
| High‑dose melphalan delivered into the liver followed by trifluridine‑tipiracil plus bevacizumab versus trifluridine‑tipiracil plus bevacizumab alone for liver‑dominant metastatic colorectal cancer | Phase 2 | Duarte, California and 19 other locations | Recruiting | Sep 23, 2024 |
| Combination treatment for advanced colorectal cancer using radiofrequency and chemotherapy | — | Berlin | Recruiting | Aug 14, 2023 |
All recruiting trials (4)
-
Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies
This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.
-
Suvemcitug plus trifluridine/tipiracil for refractory metastatic colorectal cancer
This trial will test whether adding suvemcitug to trifluridine/tipiracil helps people with refractory metastatic colorectal cancer who have already had standard chemotherapy.
-
High‑dose melphalan delivered into the liver followed by trifluridine‑tipiracil plus bevacizumab versus trifluridine‑tipiracil plus bevacizumab alone for liver‑dominant metastatic colorectal cancer
This test sees if giving high‑dose melphalan directly into the liver followed by trifluridine‑tipiracil plus bevacizumab helps people with liver‑dominant metastatic colorectal cancer more than the drugs alone.
-
Combination treatment for advanced colorectal cancer using radiofrequency and chemotherapy
This study is testing a new combination of radiofrequency treatment and two medications to see if it can help people with advanced colorectal cancer that has spread to the liver.
Related topics
Quick answers
How many Refractory Metastatic Colorectal Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in China (2 trials), Germany (2 trials), Czechia (1 trial), Italy (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.